Detail akcie Astra Zeneca online

Business Summary: AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
Financial Summary: BRIEF: For the three months ended 31 March 2022, AstraZeneca plc revenues increased 56% to $11.39B. Net income decreased 75% to $386M. Revenues reflect Farxiga segment increase of 60% to $1B, Calquenc segment increase of 98% to $414M, United States segment increase of 79% to $4.13B, EX-China segment increase of 91% to $1.74B. Net income was offset by acquisition-related costs and credits increase from $0K to $1.18B (expense).